Table 1.

ARIA‐EAACI statement

1	In areas where COVID‐19 is prevalent, screening protocols for COVID‐­19 should be applied to anyone having worsening respiratory symptoms, and personal protective equipment should be used.
2	In areas where COVID‐19 is prevalent, lung function testing procedures should be postponed if not deemed absolutely necessary; portable personal devices measuring PEF and FEV1 can be used in the meantime to monitor asthma control using the telemedicine approach.
3	In accordance with the Global Initiative for Asthma (GINA) (https://ginasthma.org/recommendations‐for‐inhaled‐asthma‐controller‐medications/), patients with asthma should not stop their prescribed inhaled corticosteroid controller medication (or prescribed oral corticosteroids). Stopping inhaled corticosteroids may have serious consequences.
4	Long‐term oral corticosteroids may sometimes be required to treat severe asthma, and it may be dangerous to stop them suddenly (GINA).
5	Oral steroids should continue to be used to treat severe asthma exacerbations.
6	In patients infected by SARS‐CoV‐2 (symptomatic or asymptomatic), nebulization (which increases the risk of deposition of the virus into the lower airways) should be replaced by spacers of large capacity.
7	In accordance with the NICE, in non‐SARS‐CoV‐2 infected patients, we propose(https://www.nice.org.uk/guidance/ng166/chapter/3‐Treatment#patients‐having‐biological‐treatment): To continue biologics because there is no evidence that biological therapies for asthma suppress immunity If the patient usually attends a hospital for biological treatments, to think about if he/she can be trained to self‐administer or could be treated at a community clinic or at home To carry out routine monitoring of biological treatment remotely if possible
8	In SARS‐CoV‐2‐infected patients, in accordance with the EAACI, we propose to cease the treatment until resolution of the disease is established. Thereafter, the administration of the biological should be re‐initiated.